Company announcement 01/2023.

Roskilde, March 16. 2023

Apillet ApS, a Danish biotech company, develops gastro resistant enteric encapsulations for oral delivery of Biopharmaceuticals, Sensitive pharmaceuticals, Probiotics and Nutraceuticals, today announces the identification of Commercially available bacterial cellulose for its APIVault encapsulation material.

The APIVault encapsulation material is produced solely from natural materials with a combination of bacterial cellulose and cellulases. The commercially available bacterial cellulose meets the requirements for the APIVault encapsulation. The encapsulation can be programmed to release the substance at a predetermined location in the small intestine or in the colon.

Apillet has determined properties of Bacterial cellulose from commercial vendors. We have identified several vendors capable of consistently delivering the appropriate quality of Bacterial cellulose. Furthermore, the passive diffusion across bacterial cellulose is very limited under gastrointestinal  conditions, showing that bacterial cellulose is an excellent constituent of the 2-combo material.

Apillet is currently defining additional development work and is actively looking for additional investments or pharma collaborations for the development of APIVault.

About APILLET ApS

Apillet ApS is a biotech company based in Roskilde Denmark, that develops gastro resistant enteric encapsulations for oral delivery of Biopharmaceuticals, Sensitive pharmaceuticals, Probiotics and Nutraceuticals.

Further information:

CEO Anders B. Christensen, cell +45 5178 0684, email: anders.christensenapillet.com

CFO Carsten L. Petersen, cell +45 2346 2718, email  carsten.petersenapillet.com

Apillet ApS
Ternevej 45
4000 Roskilde, Denmark
CVR. 39601230